Search - tctmd.com

Displaying 241 - 260 of 417

Sort: Relevancy | Date

News Daily News

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

Shelley Wood

July 25, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for June 2022

Caitlin E. Cox

July 04, 2022

News Daily News

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

L.A. McKeown

June 21, 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

Todd Neale

May 31, 2022

News Conference News ESC Heart Failure 2022

Patch-Pump Delivery of Subcutaneous Furosemide Opens Options in HF

Shelley Wood

May 26, 2022

News Conference News ESC Heart Failure 2022

HF Triple Therapy Doesn’t Seem Effective in True Preserved HF

Shelley Wood

May 25, 2022

News Conference News ESC Heart Failure 2022

Sweet Spot for Omecamtiv Mecarbil in HFrEF May Lie in Low SBP Patients

Shelley Wood

May 23, 2022

News Conference News ESC Heart Failure 2022

Dapagliflozin Boosts Health Status Across LVEF Range

Shelley Wood

May 23, 2022

News Conference News ESC Heart Failure 2022

Speech-Recognition Tool May Predict Worsening Congestion in HF

Shelley Wood

May 22, 2022

News Daily News ESC Heart Failure 2022

SERENADE: No Benefit, Possible Harm With Macitentan in HFpEF and PAH

Shelley Wood

May 22, 2022

News Conference News EuroPCR 2022

MitraClip ‘Bridge’ Strategy Continues to Help Sickest HF Patients

Michael O'Riordan

May 20, 2022

News Conference News EuroPCR 2022

MitraClip Helps for Atrial Functional MR: MITRA-TUNE

Michael O'Riordan

May 19, 2022

News Daily News

The Hunt for Protein Culprits in COVID-19’s Cardiac Complications

Michael O'Riordan

May 06, 2022

News Daily News

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

L.A. McKeown

May 05, 2022

News Daily News

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

Caitlin E. Cox

May 03, 2022

News Conference News HRS 2022

Gains in HF Drug Therapy Raise Questions About ICD Benefit in Modern Era

Todd Neale

May 02, 2022

News Daily News

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Michael O'Riordan

April 29, 2022

Presentation ARCH 2022

First Things First – Pharmacotherapy for HFrEF

Presenter: Georges Chahoud

April 23, 2022

Presentation ARCH 2022

Candidate Selection for Advanced Heart Failure Therapies: 2022

Presenter: Gregory Ewald

April 23, 2022

News Daily News

CVD Hospitalizations Spiked in Aftermath of 2020 US Election

Michael O'Riordan

April 22, 2022

Advertisement

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

TCTMD’s Top 10 Most Popular Stories for June 2022

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

Patch-Pump Delivery of Subcutaneous Furosemide Opens Options in HF

HF Triple Therapy Doesn’t Seem Effective in True Preserved HF

Sweet Spot for Omecamtiv Mecarbil in HFrEF May Lie in Low SBP Patients

Dapagliflozin Boosts Health Status Across LVEF Range

Speech-Recognition Tool May Predict Worsening Congestion in HF

SERENADE: No Benefit, Possible Harm With Macitentan in HFpEF and PAH

MitraClip ‘Bridge’ Strategy Continues to Help Sickest HF Patients

MitraClip Helps for Atrial Functional MR: MITRA-TUNE

The Hunt for Protein Culprits in COVID-19’s Cardiac Complications

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

Gains in HF Drug Therapy Raise Questions About ICD Benefit in Modern Era

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

First Things First – Pharmacotherapy for HFrEF

Candidate Selection for Advanced Heart Failure Therapies: 2022

CVD Hospitalizations Spiked in Aftermath of 2020 US Election

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content